Why Dying Liver Cells Drive MASH

A review published September 9, 2026 in Pharmacology & Therapeutics traces a specific chain of events inside a damaged liver. Cholesterol builds up inside liver cells, crystallizes, and kills the cell. The dead cell draws a ring of immune cells called macrophages around it, a pattern researchers call a crown-like structure. Tetsuya Suganami and colleagues argue this cycle, not fat buildup on its own, is what pushes metabolic dysfunction-associated steatohepatitis (MASH) toward liver scarring^[1]. The paper arrives about a year after semaglutide, the GLP-1 (glucagon-like peptide-1) drug sold as Wegovy and Ozempic, became the first medicine the FDA approved specifically for MASH.

What the new research found

MASH stands for metabolic dysfunction-associated steatohepatitis. Fat builds up in the liver first, a stage doctors call steatosis, and in a subset of patients the tissue becomes inflamed enough to scar over time, a process called fibrosis. Suganami's team asked a narrower question inside that chain: what actually kills the liver cells that set off the inflammation? Working in mouse models, the researchers found that excess cholesterol inside hepatocytes, the liver's main working cells, can crystallize and damage the cell from within^[1].

Macrophages, the immune cells that clear away dead tissue, then swarm each dying hepatocyte and form a ring around it. That ring is the crown-like structure the paper is named for. Repeated across enough of the liver, the pattern produces inflammation that does not resolve on its own^[1]. The researchers also tested a possible countermeasure: a liver-targeted compound called betaCD-PRX eased stress inside the macrophages and reduced liver fibrosis in the mouse models, without changing the animals' body weight or the amount of fat stored in the liver^[1]. That detail matters because it separates the cell-death pathway the paper describes from the weight-loss pathway that drugs like semaglutide work through.

The authors position crown-like structures as more than a liver-specific curiosity. The same pattern, a dead cell with a ring of macrophages around it, is well documented in visceral fat tissue in obesity research, where it marks dying fat cells rather than dying liver cells^[5]. Seeing the same structure in the liver is part of what leads Suganami's team to argue that hepatocyte death and the immune response to it could be a shared mechanism across more than one metabolic disease, not just MASH^[1].

Why MASH has been hard to treat

Until August 15, 2025, no drug had FDA approval for the liver disease itself, only for the metabolic conditions that often come with it. That changed when the FDA granted accelerated approval to Wegovy for noncirrhotic MASH with moderate to advanced liver fibrosis, consistent with fibrosis stages F2 to F3^[3][4].

That approval rested on the Phase 3 ESSENCE trial, which enrolled roughly 800 adults with biopsy-confirmed MASH and stage 2 or 3 fibrosis, then followed them for over a year. Patients in the trial's semaglutide arm received semaglutide 2.4 mg weekly, the same dose approved for chronic weight management under the Wegovy brand^[2]. 62.9% of the 534 patients on semaglutide had their steatohepatitis resolve with no worsening of fibrosis, versus 34.3% on placebo. 36.8% had their fibrosis improve with no worsening of steatohepatitis, versus 22.4% on placebo^[2]. Both outcomes came alongside meaningful weight loss: a mean reduction of 10.5% of body weight on semaglutide, versus 2.0% on placebo^[2]. The approval covers the fibrosis stages the trial studied and does not extend to patients with cirrhosis. It is also an accelerated approval: the FDA is requiring an ongoing second part of the ESSENCE trial to confirm that semaglutide lowers the risk of liver-related clinical events at 240 weeks before the approval becomes permanent^[4].

What this is not

The crown-like-structure research is animal work testing an experimental compound, not a medicine available to patients. BetaCD-PRX has not been studied in humans, and the paper does not claim it should replace semaglutide or any other approved MASH treatment^[1]. It is also a different mechanism. Semaglutide acts on GLP-1 receptors to reduce appetite and change how the body handles glucose and fat. The pathway Suganami's team describes is specific to how the liver responds once hepatocyte damage has already started.

The review does not settle how the two mechanisms interact, or whether targeting hepatocyte death directly would help patients who do not fully respond to semaglutide. Suganami and colleagues frame crown-like structures as a pattern that may show up across several metabolic diseases, but that is a hypothesis for future study, not a demonstrated treatment strategy^[1].

Why this matters

MASH now has one FDA-approved drug, and it works by changing weight and metabolic signaling rather than by targeting the specific cell-death process this review describes. That gap is exactly why mechanistic papers like Suganami's draw attention: they sketch out a rationale for a second class of MASH treatments that could eventually work alongside semaglutide or reach patients for whom it is not enough. None of that exists outside mouse models today. The option a clinician can actually prescribe right now is the one that already cleared FDA review.